SAN FRANCISCO, Oct. 10, 2024 /PRNewswire/ -- The Spoonful of Laughter campaign is a national initiative using comedy to educate about diabetes, counter harmful stereotypes and stigma, and amplify authentic, respectful, and empowering representations of people living with diabetes. The campaign is from the diaTribe Foundation, a nonprofit dedicated to diabetes education and advocacy, and a leader in the movement to end diabetes stigma. The Spoonful of Laughter campaign is a national initiative using comedy t ...

Insulet Corp.'s (PODD) recent FDA approval of Omnipod 5 for type 2 diabetes patients is set to expand the product's market potential. The planned launch of Omnipod 5 with Abbott's Freestyle Libre 2 Plus sensor is likely to drive further growth in the U.S. markets. Robust financial strength also bodes well for the stock. However, the rising economic uncertainty and competitive pressures remain concerns for the company. In the past year, this Zacks Rank #3 (Hold) stock has rallied 7.6% compared with the 15.5% ...

UKRAINE - 2021/06/11: In this photo illustration an Insulet Corporation logo is seen on a smartphone ... [+] and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over this period. The two stocks that focus on the glucose monitoring ...

The company had encouraging news to impart about its leading insulin pump. Specialty device maker Insulet (PODD 0.36%) had some good news to impart to the world early this week, and investors jumped on the stock as a result. As the market started to prepare for its weekend early Friday, Insulet's share price had risen by almost 11% week to date, according to data compiled by S&P Global Market Intelligence. New approval granted Insulet specializes in insulin pumps, and on Monday it formally announced its lat ...

Insulet Corp.'s (PODD) groundbreaking Omnipod 5 Automated Insulin Delivery ("AID") system (Omnipod 5) received the FDA's approval for use by type 2 diabetes patients (ages 18 years and above). The news comes after the company submitted 510(k) for an expanded indication of Omnipod 5 to the FDA, in June 2024, based on the favorable clinical outcomes of the SECURE-T2D pivotal trial. With this development, Omnipod 5 is the first and only AID system indicated for both type 1 and type 2 diabetes. Insulet's Robust ...

Key Takeaways Shares of Insulet and DexCom, which provide devices for patients with diabetes, were the weakestperforming S&P 500 stocks on Tuesday. The losses for the medtech stocks came after Eli Lilly said its blockbuster drug effectively reduced the risk of patients developing type 2 diabetes. Insulet and DexCom have been navigating headwinds related to their user growth outlook. Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled ...

Key Takeaways Insulet shares tumbled Friday after the maker of insulin management devices suggested new user growth could be lower than previously expected in the second half of 2024. Strong sales of its Omnipod device helped Insulet top second-quarter revenue expectations. The company raised its guidance for full-year revenue growth. Shares of Insulet (PODD) suffered the heaviest losses of any S&P 500 stock on Friday, dropping 8.8% after the maker of insulin management devices suggested new user growth cou ...

Insulet Corporation (PODD) reported second-quarter 2024 adjusted earnings per share (EPS) of 55 cents, up significantly 44.7% from the year-ago period's figure. The bottom line missed the Zacks Consensus Estimate by 3.5%. GAAP EPS was $2.59 compared with the year-ago figure of 39 cents. Q2 Revenues Revenues totaled $488.5 million, which beat the Zacks Consensus Estimate by 5.5%. The top line jumped 23.2% year over year (up 23.4% at the constant exchange rate or CER). CER growth exceeded the company's guidan ...

| --- | --- | --- | --- | --- | |------------------|-------|-------------------|-------|-------| | | | | | | | | | Mattie | | | | | | Podder since 2010 | | | | | | | | | | | | | | | | Insulet | | | | | | Corporation | | | | | | Q2'24 Earnings | | | | | | August 8, 2024 | | | | | This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials and the approval of products by regulat ...

Insulet Corporation (NASDAQ:PODD) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President & Chief Executive Officer Ana Maria Chadwick - Executive Vice President & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Jeff Johnson - Baird Larry Biegelsen - Wells Fargo Margaret Kaczor - William Blair Travis Steed - Bank of America Michael Polark - Wolfe Research Matt Taylor - Jeffe ...